Chimerix Stock

Chimerix Operating Expenses

Delisted·Apr 17, 2025

The Total Operating Expenses of Chimerix (CMRX) as of Aug 26, 2026 is 96.78 M USD. In the previous year, Total Operating Expenses was 93.39 M USD — a change of 3.63% (higher).

Operating Expenses

96.78 MUSD

YoY

3.63%

Last updated:

Total Operating Expenses of Chimerix is 2026 96.78 M USD. Total Operating Expenses of Chimerix was 2025 93.39 M USD. It decreases by 3.63% higher compared to the previous year.

The Chimerix Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2017
76.60 M USD
Jan 1, 2018
78.82 M USD
Jan 1, 2019
63.46 M USD
Jan 1, 2020
49.89 M USD
Jan 1, 2021
92.49 M USD
Jan 1, 2022
93.76 M USD
Jan 1, 2023
93.39 M USD
Jan 1, 2024
96.78 M USD
The Chimerix Operating Expenses history
YEAROperating ExpensesYoY
96.78 MUSD+3.63%
93.39 MUSD-0.40%
93.76 MUSD+1.38%
92.49 MUSD+85.39%
49.89 MUSD-21.38%
63.46 MUSD-19.49%
78.82 MUSD+2.90%
76.60 MUSD-8.44%
83.65 MUSD-35.16%
129.01 MUSD+105.09%
62.91 MUSD
Access this data via the Eulerpool API

Chimerix Stock analysis

What does Chimerix do? Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Chimerix stock

Total Operating Expenses of Chimerix is 96.78 M USD in 2026.

Total Operating Expenses of Chimerix changed from 93.39 M USD to 96.78 M USD, representing a 3.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Chimerix since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Chimerix historically and in real time.

Access this data via the Eulerpool API

Income Statement — Chimerix

All Key Metrics — Chimerix